Table 1 Clinical and cellular characteristics of responders and non-responders

Total

7

15

Age

68.0 (60.6–73.5)

66.0 (64.5–70.5)

ND

0.97

Female (%)

7 (100)

12 (80)

0.00 (0.00–5.3)

0.52

BMI

19.5 (18.9–23.0)

24.3 (22.2–26.0)

ND

0.09

Smoking history (%)

0 (0)

3 (23.4)

Inf (0.15–Inf)

0.52

Duration of RA (years)

11.1 (7.1–22.7)

13.0 (5.6–19.7)

ND

0.78

CRP (mg/dL)

0.6 (0.4–1.3)

0.7 (0.3–1.8)

ND

0.67

ESR (mm/h)

30.0 (24.0–39.5)

35.0 (18.0–49.0)

ND

0.80

RF positivity (%)

6 (85.7)

13 (86.7)

1.08 (0.02–24.8)

1.00

Anti-CCP positivity (%)

7 (100)

11 (73.3)

0 (0–3.2)

0.26

MTX usage (%)

3 (42.9)

9 (60.0)

1.94 (0.23–18.5)

0.65

MTX dosage^† (mg/week)

0.0 (0.0–6.0)

6.0 (0.0–8.0)

ND

0.46

PSL usage (%)

2 (28.6)

8 (53.3)

2.7 (0.3–37.4)

0.38

PSL dosage^† (mg/day)

0.0 (0.0–2.5)

6.0 (0.0–8.0)

ND

0.46

Previous b/tsDMARDs usage (%)

3 (42.9)

6 (40.0)

0.89 (0.10–8.43)

1.00

cDMARDs usage (%)

4 (57.1)

11 (73.3)

1.99 (0.20–19.2)

0.63

SE (%)

11 (73.3)

5 (71.4)

1.1 (0.1–11.2)

1.00

DAS28-ESR (0 months)

4.4 (4.0–4.6)

5.3 (3.5–5.6)

ND

0.36

DAS28-ESR (3 months)

2.8 (2.3–3.0)

3.4 (2.9–4.2)

ND

0.07

Cellular phenotype (× 10³/μL)

 White blood cell

5.43 (5.19–7.24)

7.18 (5.15–10.6)

ND

0.62

 Neutrophil

3.75 (3.12–5.12)

4.92 (3.29–8.86)

ND

0.53

 Lymphocyte

1.40 (1.10–1.70)

1.20 (1.00–1.30)

ND

0.32

 CD3 + cell

1.02 (0.77–1.16)

0.72 (0.49–0.88)

ND

0.09

 CD19 + cell

0.19 (0.10–0.20)

0.11 (0.07–0.24)

ND

0.78

 CD56 + cell

0.23 (0.19–0.28)

0.22 (0.16–0.32)

ND

0.83

 Monocyte

0.28 (0.23–0.30)

0.43 (0.31–0.55)

ND

0.02

 Eosinophil

0.13 (0.04–0.21)

0.10 (0.05–0.18)

ND

0.86

 Basophil

0.03 (0.02–0.06)

0.07 (0.03–0.08)

ND

0.62